• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 22, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Early detection of prediabetes can reduce risk of developing cardiovascular disease

Bioengineer by Bioengineer
January 22, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

WINSTON-SALEM, N.C. – Jan. 23, 2019 – A diagnosis of prediabetes should be a warning for people to make lifestyle changes to prevent both full-blown diabetes and cardiovascular disease (CVD), according to scientists at Wake Forest School of Medicine.

“We know that having diabetes increases the risk of developing cardiovascular disease, so in our study we wanted to determine what the absolute risk or probability of developing heart disease was for people who were only at a pre-diabetic level of blood sugar,” said the study’s lead author Michael P. Bancks, Ph.D., assistant professor of epidemiology and prevention at Wake Forest’s medical school, a part of Wake Forest Baptist Health.

The study is published in the current issue of Diabetes Care.

Prediabetes is indicated by a fasting blood sugar level between100 and 125 mg/dL (5.6 to 6.9 mmol/L), while a fasting blood sugar level of less than 100 mg/dL (5.6 mmol/L) is considered normal. A level of 126 mg/dL (7 mmol/L) and higher is the diagnostic threshold for diabetes, Bancks said.

In the study, the researchers used data from seven observational studies that included both white and black men and women who were followed from 1960 through 2015. Prior research focused on white Americans of European descent, whereas this study included African-Americans so the findings could be generalized to a broader population, Bancks said.

The sample included 19,630 individuals who had not had a prior CVD event, considered here as heart disease or stroke. Absolute risk of CVD was determined through analysis of participants’ fasting glucose category beginning at age 55 through 85.

Bancks and colleagues found that the risk for CVD ranged from 15 percent (non-diabetic) to 38 percent (diabetic) among women and from 21 percent (non-diabetic) to 47 percent (diabetic) among men. Increases in glucose to the diabetic level during mid-life were associated with substantially higher cardiovascular risk than when glucose levels stayed below the diabetes threshold.

“Although we found that individuals who had pre-diabetic levels of blood glucose did not have a higher absolute risk for cardiovascular disease, we know that most people go on to develop diabetes unless they take measures to reduce their blood sugar levels,” Bancks said.

“Our study provides further evidence that if you can avoid diabetes you may be able to stave off cardiovascular disease. Pre-diabetes should serve as a red flag to doctors to closely monitor their patient’s blood sugar to try to prevent diabetes through lifestyle interventions like better diet and increased physical activity, and if necessary, with pharmacologic therapies.”

###

Co-authors are: Hongyan Ning, M.D., Mercedes R. Carnethon, Ph.D., Norrina B. Allen, Ph.D., John T. Wilkins, M.D., and Donald M. Lloyd-Jones, M.D., of Northwestern University; Alain G. Bertoni, M.D., of Wake Forest School of Medicine; Adolfo Correa, M.D., of University of Mississippi; Justin B. Echouffo Tcheugui, M.D., Johns Hopkins University; and Leslie A. Lange, Ph.D., University of Colorado Denver.

Support for the study was provided by National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health under Award Number T32HL069771 to conduct the current work. The LRPP was supported in its inception by the National Institutes of Health/National Heart, Lung, and Blood Institute grant number R21 HL085375 and is currently supported by funds from the Northwestern University Feinberg School of Medicine. The JHS is supported and conducted in collaboration with Jackson State University (HHSN268201300049C and HHSN268201300050C), Tougaloo College (HHSN268201300048C), and the University of Mississippi Medical Center (HHSN268201300046C and HHSN268201300047C) contracts from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute for Minority Health and Health Disparities (NIMHD).

Media Contact
marguerite beck
[email protected]
336-716-2415

Tags: EndocrinologyMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Top Breast Health Advocate Honored with Benjamin Spock Award for Compassion in Medicine

August 22, 2025
blank

Brain Area 46: The Hub of Emotion Regulation in Marmosets

August 22, 2025

BeginNGS® Newborn Genome Sequencing Program Expands Global Reach Through Collaboration with Sidra Medicine in Qatar

August 22, 2025

A Decade of Migrasome Research: Biogenesis, Functions, Diseases

August 22, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Molecules in Focus: Capturing the Timeless Dance of Particles

    141 shares
    Share 56 Tweet 35
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    114 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    81 shares
    Share 32 Tweet 20
  • Modified DASH Diet Reduces Blood Sugar Levels in Adults with Type 2 Diabetes, Clinical Trial Finds

    60 shares
    Share 24 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Revolutionary AI Model Promises Longer Lifespan and Enhanced Safety for Electric Vehicle Batteries

Top Breast Health Advocate Honored with Benjamin Spock Award for Compassion in Medicine

B3GNT5 Controls EMT, MET, Chemoresistance Mechanisms

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.